eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2008
vol. 33
 
Share:
Send email
Share:
abstract:

Experimental immunology
The MTT assay is not adequate for the assessment of mutated PAI-1 toxicity towards endothelial cells

Joanna Chorostowska-Wynimko
,
Marta Kędzior
,
Radosław Struniawski
,
Beata Gruber
,
Elżbieta Anuszewska
,
Ansari Aleem
,
Jerzy Jankun

Centr Eur J Immunol 2008; 33 (4): 182-184
Online publish date: 2008/12/24
View full text Get citation
 
Present study was aimed at the evaluation of the endothelial cytotoxicity of the plasminogen activator inhibitor type-1 mutated protein characterized by the very long half-life time (VLHL PAI-1) and therefore prolonged anti-proteinase activity. Viability of the human umbilical vein endothelial cells (HUVECs) cultured for 72 hours with the increasing concentrations (1, 10, 100 µg/ml) of VLHL PAI-1 was not affected as demonstrated by the neutral red test and direct cell counting. On the contrary, the classical MTT test proved to be unreliable for this experimental setting most possibly due to the cell specific VLHL PAI-1 – HUVECs interaction. This suggestion was further confirmed by the similar results of the viability assessment by the MTT test and direct cell count in the A549 and NCI-H1299 lung cancer cell lines cultures with VLHL PAI-1 mutated protein.
keywords:

PAI-1, cytotoxicity, MTT test, neutral red assay, HUVEC
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.